Marina Ciomei

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 308 citations · Full text

Bombesin stimulates growth of human prostatic cancer cellsin vitro

Mauro Bologna, Claudio Festuccia, Paola Muzi et al. · Cancer · 1990 · 216 citations · Full text

Nm Bombesin, Urology, Cell Proliferation +8

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding

Paolo Pevarello, Maria Gabriella Brasca, Raffaella Amici et al. · Journal of Medicinal Chemistry · 2004 · 157 citations · Full text

Drug Target, Lead Identification, Pharmacotherapy +23

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

Gianluca Papeo, Helena Posteri, Daniela Borghi et al. · Journal of Medicinal Chemistry · 2015 · 139 citations · Full text

Cancer Therapy, Drug Target, Pharmacotherapy +18

Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor

Maria Gabriella Brasca, Nadia Amboldi, Dario Ballinari et al. · Journal of Medicinal Chemistry · 2009 · 125 citations · Full text

Drug Target, Chemoprevention Strategy, Gynecology +18